Two new indications for pembrolizumab have been approved in Russia
.
Main Author: | article Editorial |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2020-11-01
|
Series: | Opuholi Ženskoj Reproduktivnoj Sistemy |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/739 |
Similar Items
-
In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
by: Article Editorial
Published: (2020-01-01) -
New indications for the use of pembrolizumab in Russia: the use of the drug in the 1st line of treatment of recurrent and metastatic head and neck squamous cell carcinoma in single mode and in combination with chemotherapy has been approved
by: Article Editorial
Published: (2020-11-01) -
Proceedings of the Expert Council “Treatment of inoperable endometrial cancer in Russia: issues that have not yet been addressed”
by: article Editorial
Published: (2021-06-01) -
What has been achieved and what has not been achieved in 2020
by: article Editorial
Published: (2021-04-01) -
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
by: Michael M. Boyiadzis, et al.
Published: (2018-05-01)